Tag Archives: BIO Investor Forum

Positive Palifosfamide Sarcoma Phase II Data from ZIOPHARM

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced positive data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed. As a result of reaching a key efficacy milestone and following safety and efficacy data review by the Data Committee, sarcoma experts, and the Company’s Medical Advisory Board, made the decision Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Positive clinical trial results for Epeius

Epeius Biotechnologies Corporation announced results of its Rexin-G®  clinical trials. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has shown benefits of remission in otherwise intractable metastatic cancers. Three recent cases of Stage IV metastatic cancer, namely (i) osteosarcoma, (ii) prostate cancer, and (iii) pancreas cancer, demonstrated that Rexin-G treatments alone led to clinical remission of disease in patients. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Locus Pharmaceuticals and Novartis enter into research collaboration

Locus Pharmaceuticals has entered into a discovery research collaboration with Novartis. Locus will collaborate with Novartis to discover novel chemotypes on targets of interest to Novartis’ select therapeutic areas.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

UsiRNA reduces tumor growth in vivo

MDRNA, Inc. (NASDAQ: MRNA) presented new in vivo data showing continued progress in the advancement of the Company’s oncology program. J. Michael French, President and CEO, reported that MDRNA’s UsiRNAs, delivered by the Company’s DiLA2 platform, down-regulated a previously “non-druggable” target with subsequent reductions in tumor growth in models of liver and bladder cancer via both systemic and local delivery.  Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Medicago awarded U.S. Army contract

Medicago Inc. (TSX-V: MDG) has been awarded a proof of concept contract by the U.S. Army Research, Development and Engineering Command laboratory specifically the Edgewood Chemical Biological Center (“ECBC”) Research & Technology Directorate. Medicago will work with ECBC to investigate the affordable production of industrial enzymes in the field of biofuels. This new project builds on Medicago’s proprietary plant-based manufacturing platform and its potential for applications beyond the biological drug market. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,